NEW YORK (GenomeWeb News) – HandyLab said this week that Qiagen has licensed the firm's extraction technology for use in the sample preparation part of its human papillomavirus assays.

Ann Arbor, Mich.-based HandyLab said its extraction technology would be used with the HPV molecular diagnostic tests on Qiagen's QIAensemble and QIAsymphony random access platforms. Financial and other terms of the license were not disclosed.

HandyLab is a privately-held molecular diagnostics company developing products for the decentralization of nucleic acid testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.